Proteinase-activated receptor 2: Differential activation of the receptor by tethered ligand and soluble peptide analogs

被引:39
作者
Al-Ani, B
Wijesuriya, SJ
Hollenberg, MD
机构
[1] Univ Calgary, Hlth Sci Ctr,Fac Med, Dept Pharmacol & Therapeut, Diabet & Endocrine Res Grp, Calgary, AB T2N 4N1, Canada
[2] Univ Calgary, Fac Med, Dept Med, Diabet & Endocrine Res Grp, Calgary, AB T2N 4N1, Canada
关键词
D O I
10.1124/jpet.302.3.1046
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Activation of rat proteinase-activated receptor 2 (PAR2) by trypsin involves the unmasking of the tethered sequence S(37)LIGRL(42) that either tethered or on its own as a free peptide, activates PAR2. We aimed to determine whether different peptide sequences acting either as trypsin-revealed tethered ligands or as soluble peptides had the same relative activities for triggering the receptor. A comparison was also made between the different soluble and tethered receptor activating sequences in receptor constructs with extracellular loop 2 (ECL2) residues (EE233)-E-232 (PAR2SR/EE) mutated to (RR233)-R-232 (PAR2SR/RR). Using site-directed mutagenesis, we prepared PAR2 constructs with trypsin-revealed tethered ligand sequences corresponding to the synthetic receptor-activating peptides (PAR2APs): SLIGRL-NH2 (SR-NH2), SLIGAL-NH2 (SA-NH2), and SLIGEL-NH2 (SE-NH2). Kirsten virus-transformed rat kidney cells stably expressing 1) wild-type PAR2 with site-mutated tethered ligands (PAR2SA/EE and PAR2SE/EE); 2) wild-type PAR2 with ECL2 mutated to (RR233)-R-232 (PAR2SR/RR); and 3) PAR2 constructs with both the RR mutation in ECL2 and a mutation in the tethered ligand (PAR2SA/RR and PAR2SE/RR) were assessed for receptor-mediated calcium signaling and cell growth inhibition, upon activation either by trypsin or the above-mentioned PAR2APs. Trypsin exerted equivalent and full agonist activity on the PAR2 constructs, causing a maximum response between 20 to 80 nM. In contrast, the PAR2APs as free peptide agonists showed marked potency differences in all wild-type receptors with mutated tethered ligands (SR-NH2 >> SA-NH2 >> SE-NH2) and in all ECL2 RR mutated constructs (SE-NH2 > SR-NH2 >> SA-NH2). We conclude that for receptor activation, the trypsin-revealed PAR2 tethered ligand sequence interacts differently for receptor activation than does the same peptide sequence as a free peptide.
引用
收藏
页码:1046 / 1054
页数:9
相关论文
共 19 条
[1]  
Al-Ani B, 1999, J PHARMACOL EXP THER, V290, P753
[2]   Proteinase activated receptor 2: role of extracellular loop 2 for ligand-mediated activation [J].
Al-Ani, B ;
Saifeddine, M ;
Kawabata, A ;
Hollenberg, MD .
BRITISH JOURNAL OF PHARMACOLOGY, 1999, 128 (05) :1105-1113
[3]   DETECTION OF FUNCTIONAL RECEPTORS FOR THE PROTEINASE-ACTIVATED-RECEPTOR-2-ACTIVATING POLYPEPTIDE, SLIGRL-NH2, IN RAT VASCULAR AND GASTRIC SMOOTH-MUSCLE [J].
ALANI, B ;
SAIFEDDINE, M ;
HOLLENBERG, MD .
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 1995, 73 (08) :1203-1207
[4]   Extracellular mutations of protease-activated receptor-1 result in differential activation by thrombin and thrombin receptor agonist peptide [J].
Blackhart, BD ;
Ruslim-Litrus, L ;
Lu, CC ;
Alves, VL ;
Teng, W ;
Scarborough, RM ;
Reynolds, EE ;
Oksenberg, D .
MOLECULAR PHARMACOLOGY, 2000, 58 (06) :1178-1187
[5]  
Bohm SK, 1996, BIOCHEM J, V314, P1009
[6]   A protective role for protease-activated receptors in the airways [J].
Cocks, TM ;
Fong, B ;
Chow, JM ;
Anderson, GP ;
Frauman, AG ;
Goldie, RG ;
Henry, PJ ;
Carr, MJ ;
Hamilton, JR ;
Moffatt, JD .
NATURE, 1999, 398 (6723) :156-160
[7]   A polymorphic protease-activated receptor 2 (PAR2) displaying reduced sensitivity to trypsin and differential responses to PAR agonists [J].
Compton, SJ ;
Cairns, JA ;
Palmer, KJ ;
Al-Ani, B ;
Hollenberg, MD ;
Walls, AF .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (50) :39207-39212
[8]   SPECIFICITY OF THE THROMBIN RECEPTOR FOR AGONIST PEPTIDE IS DEFINED BY ITS EXTRACELLULAR SURFACE [J].
GERSZTEN, RE ;
CHEN, J ;
ISHII, M ;
ISHII, K ;
WANG, L ;
NANEVICZ, T ;
TURCK, CW ;
VU, TKH ;
COUGHLIN, SR .
NATURE, 1994, 368 (6472) :648-651
[9]  
Hollenberg MD, 1996, MOL PHARMACOL, V49, P229
[10]   Proteinase-activated receptors: structural requirements for activity, receptor cross-reactivity, and receptor selectivity of receptor-activating peptides [J].
Hollenberg, MD ;
Saifeddine, M ;
AlAni, B ;
Kawabata, A .
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 1997, 75 (07) :832-841